Beeline Medicines announced the closing of a $126.3 million Series A extension. The new funding brings the company’s total Series A financing round to $426.3 million. The extension adds to Beeline Medicines’ previously announced $300 million Series A financing. The funding came from existing shareholders and investors, including Bain Capital, Canada Pension Plan Investment Board, Bristol Myers Squibb, and certain members of the company’s management team.
Beeline Medicines is a clinical-stage biotechnology company focused on precision therapies for autoimmune and inflammatory diseases. The company plans to use the proceeds to support several clinical studies across its immunology portfolio.
The funding will also support planned pivotal development of afimetoran, Beeline Medicines’ lead program, in lupus. Afimetoran is a selective, small molecule, once-daily, equipotent TLR7/8 inhibitor with potential to become a best-in-disease oral therapy for lupus.
The company has started pivotal development preparations in lupus. Beeline expects a Phase 2 readout of afimetoran in systemic lupus erythematosus in the second half of 2026.
Beeline Medicines was formed in July 2025. Since then, the company has assembled an executive leadership team with experience in drug discovery, clinical development, and global commercialization across multiple therapeutic areas.
The company is advancing a portfolio of selective therapeutic candidates with biologically validated mechanisms. Beeline’s strategy is focused on targeting the underlying causes of immune-mediated diseases and improving patient outcomes.
Beeline is also advancing BLN-326, formerly BMS-986326. The candidate is an IL-2-CD25 fusion protein with potential in diseases characterized by regulatory T cell and effector T cell imbalance, including atopic dermatitis and lupus, where Phase 1b studies are ongoing.
Over the next 12 months, Beeline expects to initiate additional clinical trials across its pipeline. These include studies for lomedeucitinib, an allosteric TYK2 inhibitor with potential as a first-in-class therapy for rare autoimmune and inflammatory conditions.
The company also plans to advance BLN-481, formerly BMS-986481, a novel anti-IL-18 receptor beta antibody. A Phase 1 single- and multiple-ascending-dose study in healthy volunteers is planned.
Beeline is also continuing preclinical development of BLN-498, formerly BMS-986498. The candidate is a potentially first-in-class myeloid-selective IL-10 therapeutic.
KEY QUOTE:
“The strong participation of our existing equity holders in this extension, completed ahead of our anticipated Phase 2 readout for afimetoran in systemic lupus, reflects deep conviction in the opportunity ahead of us to deliver life-changing treatment options for people with immune-mediated diseases, starting with lupus patients. This additional capital provides us with increased operating flexibility as we focus on preparing our lead program for pivotal development and advancing our broader pipeline to deliver differentiated, lasting impact for patients.”
Saqib Islam, CEO of Beeline Medicines
